Provention Bio, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics aimed at intercepting and preventing immune-mediated diseases.
-We seek technologies or targets designed to predict, preempt or intervene before immune disease begins, re-appears or progresses.
-We are creating a new biopharmaceutical category for autoimmunity.
We leverage a transformational drug development strategy that sources, repositions and advances candidates that:
-Target the interception or prevention of immune-mediated disease
-Have been underdeveloped or deprioritized because of insufficient clinical trial efficacy or for strategic reasons
-Have demonstrated proof-of-mechanism by preventing or intercepting immunopathologic pathways
We believe that our deep understanding of immune-mediated pathophysiology, experience in translational medicine, and expertise in the design of rapid go/no-go clinical trials enables us to identify and evaluate potential therapeutic candidates for acquisition or in-licensing.